MYGN - Sector: Healthcare---Industry: Biotechnology & Drugs

[setravis]

MYGN - Possible Breakout...

Myriad Genetics, Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products.


52wk Range: 34.35 - 67.40
Volume: 1,055,586
Avg Vol (3m): 1,724,610

Technicals
Last Price Quote is:
5.96%above 13-day MA
21.32%above 50-day MA
RS Rating: 97  

Fundamentals
Key Data:
Market Cap (M): $2,954.94  
P/E Ratio: NA  
PEG Ratio: N/A  
Next Earnings: 08/19/2008
Last Analyst Rating: Outperform

[setravis]

Profile : 


Myriad Genetics Inc.
320 Wakara Way
Salt Lake City, UT 84108
United States - Map
Phone: 801-584-3600
Fax: 801-584-3640
Web Site: http://www.myriad.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Diagnostic Substances
Full Time Employees: 848


BUSINESS SUMMARY   
Myriad Genetics, Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products. The company offers molecular diagnostic products comprising BRACAnalysis for assessing a woman's risk for breast and ovarian cancer; COLARIS for determining a person's risk of developing colorectal cancer or uterine cancer; COLARIS AP for assessing a person's risk of developing colon cancer; MELARIS for determining a person's risk of developing melanoma; and THERAGUIDE 5-FU for assessing a patient's risk of developing 5-FU toxicity. It markets these products through its own sales force in the United States and through marketing collaborations in selected foreign countries. The company's developing therapeutic products include Flurizan, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Azixa, a Phase II clinical trial product for solid primary and metastatic brain tumors; MPC-2130, which is in Phase I clinical trial for the treatment of hematologic cancer; MPC-0920, a Phase I clinical trial product for thrombosis; and Vivecon, which is in late-stage preclinical development for the treatment of AIDS. Myriad Genetics was founded in 1991 and is headquartered in Salt Lake City, Utah.

[setravis]

A stock Near 52-Week High.......Hitting High Notes

Recent CandleStick Analysis
Neutral
Feb-12-2009 Bullish Engulfing 
Feb-11-2009 DOJI 

Support @ $80.62...73.86...72.01
Resistance @ $85.68...87.05

MACD is very bullish
Stochastic is very bullish

52wk Range: 34.35 - 88.40
Volume: 589,469
Avg Vol (3m): 980,468
Market Cap: 3.99B
P/E (ttm): 43.31 x
EPS (ttm): 1.97
Div & Yield: N/A (N/A)

Technicals
Last Price Quote is:
2.55%above 13-day MA
15.66%above 50-day MA
RS Rating: 89 

Fundamentals
Key Data:
Market Cap (M): $4,094.95 
P/E Ratio: 43.22 
PEG Ratio: 2.024 
Next Earnings: 05/05/2009
Last Analyst Rating: Buy